Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTMI6F5)

DTT Name	Transient receptor potential cation channel V1 (TRPV1)
Synonyms	Vanilloid receptor 1; VR1; TrpV1; Transient receptor potential cation channel subfamily V member 1; Osm-9-like TRP channel 1; OTRPC1; Capsaicin receptor
Gene Name	TRPV1
DTT Type	Successful target	[1]
BioChemical Class	Transient receptor potential catioin channel
UniProt ID	TRPV1_HUMAN
TTD ID	T83193
3D Structure	Download 2D Sequence (FASTA) Download 3D Structure (PDB) Download
Sequence	MKKWSSTDLGAAADPLQKDTCPDPLDGDPNSRPPPAKPQLSTAKSRTRLFGKGDSEEAFP VDCPHEEGELDSCPTITVSPVITIQRPGDGPTGARLLSQDSVAASTEKTLRLYDRRSIFE AVAQNNCQDLESLLLFLQKSKKHLTDNEFKDPETGKTCLLKAMLNLHDGQNTTIPLLLEI ARQTDSLKELVNASYTDSYYKGQTALHIAIERRNMALVTLLVENGADVQAAAHGDFFKKT KGRPGFYFGELPLSLAACTNQLGIVKFLLQNSWQTADISARDSVGNTVLHALVEVADNTA DNTKFVTSMYNEILMLGAKLHPTLKLEELTNKKGMTPLALAAGTGKIGVLAYILQREIQE PECRHLSRKFTEWAYGPVHSSLYDLSCIDTCEKNSVLEVIAYSSSETPNRHDMLLVEPLN RLLQDKWDRFVKRIFYFNFLVYCLYMIIFTMAAYYRPVDGLPPFKMEKTGDYFRVTGEIL SVLGGVYFFFRGIQYFLQRRPSMKTLFVDSYSEMLFFLQSLFMLATVVLYFSHLKEYVAS MVFSLALGWTNMLYYTRGFQQMGIYAVMIEKMILRDLCRFMFVYIVFLFGFSTAVVTLIE DGKNDSLPSESTSHRWRGPACRPPDSSYNSLYSTCLELFKFTIGMGDLEFTENYDFKAVF IILLLAYVILTYILLLNMLIALMGETVNKIAQESKNIWKLQRAITILDTEKSFLKCMRKA FRSGKLLQVGYTPDGKDDYRWCFRVDEVNWTTWNTNVGIINEDPGNCEGVKRTLSFSLRS SRVSGRHWKNFALVPLLREASARDRQSAQPEEVYLRQFSGSLKPEDAEVFKSPAASGEK
Function	Ligand-activated non-selective calcium permeant cation channel involved in detection of noxious chemical and thermal stimuli. Seems to mediate proton influx and may be involved in intracellular acidosis in nociceptive neurons. Involved in mediation of inflammatory pain and hyperalgesia. Sensitized by a phosphatidylinositol second messenger system activated by receptor tyrosine kinases, which involves PKC isozymes and PCL. Activation by vanilloids, like capsaicin, and temperatures higher than 42 degrees Celsius, exhibits a time- and Ca(2+)-dependent outward rectification, followed by a long-lasting refractory state. Mild extracellular acidic pH (6.5) potentiates channel activation by noxious heat and vanilloids, whereas acidic conditions (pH <6) directly activate the channel. Can be activated by endogenous compounds, including 12-hydroperoxytetraenoic acid and bradykinin. Acts as ionotropic endocannabinoid receptor with central neuromodulatory effects. Triggers a form of long-term depression (TRPV1-LTD) mediated by the endocannabinoid anandamine in the hippocampus and nucleus accumbens by affecting AMPA receptors endocytosis.
KEGG Pathway	Neuroactive ligand-receptor interaction (hsa04080 ) Inflammatory mediator regulation of TRP channels (hsa04750 )
Reactome Pathway	TRP channels (R-HSA-3295583 )

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This DTT

1 Approved Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[1]
------------------------------------------------------------------------------------

16 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CNTX-4975	DMB4JPG	Knee osteoarthritis	FA01	Phase 3	[2]
DWP-05195	DMQKU2F	Neuropathic pain	8E43.0	Phase 2	[3]
GRC-15300	DMWXJSZ	Pain	MG30-MG3Z	Phase 2	[4]
PAC-14028	DM3816P	Atopic dermatitis	EA80	Phase 2	[5]
Resiniferatoxin	DMP62L5	Neuropathic pain	8E43.0	Phase 2	[6]
SB-705498	DMRYHWI	Rhinitis	FA20	Phase 2	[7]
XEN-D0501	DMG7PDY	Overactive bladder	GC50.0	Phase 2	[8]
ABT-102	DMJFWPR	Chronic pain	MG30	Phase 1	[7]
BIO-017	DMYHK3Y	Angelman syndrome	LD90.0	Phase 1	[9]
CA-011	DMPQ1TM	Chronic pain	MG30	Phase 1	[2]
GRC-6211	DMZ0D3V	Asthma	CA23	Phase 1	[10]
JNJ-39439335	DM45SGE	Musculoskeletal pain	MG30	Phase 1	[11]
MR-1817	DMVNLGW	Pain	MG30-MG3Z	Phase 1	[12]
PF-3864086	DML0OCD	Pain	MG30-MG3Z	Phase 1	[13]
PHE-377	DMUANF9	Pain	MG30-MG3Z	Phase 1	[14]
SAR-115740	DMD2VRY	Pain	MG30-MG3Z	Phase 1	[15]
------------------------------------------------------------------------------------


⏷ Show the Full List of 16 Clinical Trial Drug(s)

162 Patented Agent(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMID25666693-Compound-1	DMEL1WX	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-10	DMQP3TD	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-100	DMYTZFP	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-101	DMNOD4A	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-102	DM0OY5D	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-103	DM8DZA6	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-104	DMYCT5B	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-105	DMV509A	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-106	DMEG8CB	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-107	DMB2RML	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-108	DMN0FCA	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-109	DMWGIS7	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-11	DM9HOM6	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-110	DMNGD2S	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-111	DMNKW1E	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-112	DMQOSH5	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-113	DM02O5V	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-114	DMA9YDK	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-115	DMF5ODZ	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-116	DMNEBXL	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-117	DMN9LDH	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-118	DMBIQMS	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-119	DMD0WIA	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-12	DMVSFNE	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-120	DMVREIM	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-121	DMC1QDB	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-122	DMR63O2	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-123	DM9358G	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-124	DM6ODU7	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-125	DMR0WM1	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-126	DMKN72Y	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-127	DMCE6MB	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-128	DM6QHGV	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-129	DM74NBY	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-13	DMI0YWU	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-130	DMIX1K0	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-131	DML7SYH	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-132	DMHQM8W	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-133	DMHEPR3	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-134	DM2WJKR	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-135	DMYZVPD	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-136	DMPY1QC	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-137	DMZ7LAO	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-138	DMJLFEN	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-139	DMLMEPI	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-14	DM3D4RI	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-140	DMVQU9T	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-141	DMQGTYE	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-142	DMFKN1O	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-143	DMJP0NB	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-144	DMCXELD	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-145	DMP89E4	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-146	DMLE5BK	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-147	DMG1SYN	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-148	DM0EYON	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-149	DMPU19H	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-15	DM1G6AE	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-150	DMHMEFY	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-151	DM5CY86	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-152	DM27154	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-153	DM1FTV6	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-154	DMKNU0Z	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-155	DMZLB07	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-156	DMTVAUP	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-157	DME8LUY	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-158	DM2BTCU	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-159	DM74OGS	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-16	DM6SL9D	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-160	DM2KTAB	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-161	DM06IWA	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-162	DMXS5WY	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-17	DMRK1W7	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-18	DMKU6C3	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-19	DM63UM8	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-2	DMERD39	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-20	DM3I90D	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-21	DMUXO47	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-22	DMHPW3X	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-23	DMJ3YDT	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-24	DMUMYKX	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-25	DMI8CB3	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-26	DMQBFI2	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-27	DMKHO8T	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-28	DM7T962	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-29	DM02D1B	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-3	DMN692C	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-30	DMC3DT7	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-31	DM853Y7	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-32	DM58Z4M	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-33	DMW7981	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-34	DMWGAQU	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-35	DMG9CPH	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-36	DMWVR81	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-37	DMSR218	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-38	DMBW36Y	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-39	DML3KHF	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-4	DMBD9S5	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-40	DM58QW1	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-41	DML76MF	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-42	DM6I49E	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-43	DMTN25V	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-44	DM0I72B	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-45	DMVDKXY	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-46	DM0MEXT	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-47	DMHBN5M	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-48	DMEVL0S	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-49	DM67DEG	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-5	DM53PBG	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-50	DM4GUZO	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-51	DM3KSV9	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-52	DMQPOGC	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-53	DMKCARH	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-54	DMLW95Y	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-55	DMPE7M8	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-56	DM82BAM	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-57	DMQRFXT	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-58	DMJEH0F	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-59	DMLI1YR	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-6	DMC5W1Y	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-60	DM2C58A	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-61	DM0B578	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-62	DMDMFJG	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-63	DM6DFAK	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-64	DMDWH8T	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-65	DM1A0GT	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-66	DMD13OS	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-67	DMPV9L2	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-68	DM87HTO	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-69	DMIPFO3	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-7	DMNTVFH	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-70	DMEPYGQ	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-71	DM4VAQ3	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-72	DMW8XD2	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-73	DM9LZJ5	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-74	DM80E3F	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-75	DMNATSQ	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-76	DMYH429	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-77	DM05D48	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-78	DMQI1YN	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-79	DMTQ26G	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-8	DMZQ6HC	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-80	DMB56LS	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-81	DM5ZELW	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-82	DM1MZ70	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-83	DM2ZVXD	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-84	DM4QYIJ	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-85	DMGVU7M	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-86	DMFZ3S4	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-87	DMAV4XY	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-88	DMT9EJL	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-89	DM6RQKH	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-9	DM8A4B5	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-90	DM26NQE	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-91	DMXU3IE	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-92	DMRGOZ8	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-93	DMM5EI4	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-94	DMHREX9	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-95	DMFNB1T	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-96	DME3NTB	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-97	DMHJOP7	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-98	DM2ZR8M	Cancer related pain	MG30	Patented	[16]
PMID25666693-Compound-99	DMOISDH	Cancer related pain	MG30	Patented	[16]
------------------------------------------------------------------------------------


⏷ Show the Full List of 162 Patented Agent(s)

8 Discontinued Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AZD1386	DMFAG8W	Esophagus sensitivity	DA2Y-DA2Z	Discontinued in Phase 2	[17]
DA-5018	DM48ECA	Diabetic neuropathy	8C0Z	Discontinued in Phase 2	[18]
JTS-653	DM35CQ4	Overactive bladder	GC50.0	Discontinued in Phase 2	[19]
NGD-8243	DMOWLVF	Acute or chronic pain	MG30-MG31	Discontinued in Phase 2	[7]
Nuvanil	DMPM58S	Pain	MG30-MG3Z	Discontinued in Phase 2	[20]
AMG-517	DM3HB06	Chronic pain	MG30	Discontinued in Phase 1	[7]
AMG-8562	DMXRQS6	Pain	MG30-MG3Z	Terminated	[7]
BL-1872	DMGDTLX	Pain	MG30-MG3Z	Terminated	[21]
------------------------------------------------------------------------------------


⏷ Show the Full List of 8 Discontinued Drug(s)

1 Preclinical Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
A-425619	DMECV6L	Pain	MG30-MG3Z	Preclinical	[7]
------------------------------------------------------------------------------------

75 Investigative Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
(5E,8E,11E,14E)-Icosa-5,8,11,14-tetraenal	DM8JHWS	Discovery agent	N.A.	Investigative	[22]
(E)-3-(4-tert-Butyl-phenyl)-N-phenyl-acrylamide	DMTKCAL	Discovery agent	N.A.	Investigative	[23]
(E)-Octadec-9-enal	DMXYAIQ	Discovery agent	N.A.	Investigative	[22]
(R)-1-(1H-indazol-4-yl)-3-(1-p-tolylethyl)urea	DMYBC24	Discovery agent	N.A.	Investigative	[24]
(S)-1-(1H-indazol-4-yl)-3-(1-p-tolylethyl)urea	DMF2IY8	Discovery agent	N.A.	Investigative	[24]
1,3-dibenzyl urea	DMMOBPN	Discovery agent	N.A.	Investigative	[25]
1-(4-Bromo-benzyl)-3-quinazolin-8-yl-urea	DMTPD4R	Discovery agent	N.A.	Investigative	[26]
1-(isoquinolin-5-yl)-3-(1-phenylpropyl)urea	DMOTICP	Discovery agent	N.A.	Investigative	[24]
1-(isoquinolin-5-yl)-3-(4-morpholinobenzyl)urea	DMHWITR	Discovery agent	N.A.	Investigative	[27]
1-benzhydryl-3-(isoquinolin-5-yl)urea	DMQSK3H	Discovery agent	N.A.	Investigative	[24]
12S-HPETE	DM6ZX1O	Discovery agent	N.A.	Investigative	[28]
15S-HPETE	DM41LV6	Discovery agent	N.A.	Investigative	[28]
2-(4-pentylphenyl)-N-(pyridin-3-yl)acetamide	DMR54SW	Discovery agent	N.A.	Investigative	[29]
2-APB	DM9AKVR	Discovery agent	N.A.	Investigative	[30]
4-(3-methylpyridin-2-yl)-N-p-tolylbenzamide	DM5I6O2	Discovery agent	N.A.	Investigative	[31]
4-(butyl(methyl)amino)-N-(quinolin-3-yl)benzamide	DM3GUFI	Discovery agent	N.A.	Investigative	[29]
4-(cyclohexylamino)-N-(quinolin-3-yl)benzamide	DMWELVK	Discovery agent	N.A.	Investigative	[29]
4-(hexyl(methyl)amino)-N-(quinolin-3-yl)benzamide	DM70MRZ	Discovery agent	N.A.	Investigative	[29]
4-(methyl(nonyl)amino)-N-(quinolin-3-yl)benzamide	DM3TF9Y	Discovery agent	N.A.	Investigative	[29]
4-(methyl(octyl)amino)-N-(quinolin-3-yl)benzamide	DM1I0TA	Discovery agent	N.A.	Investigative	[29]
4-butyl-N-(7-hydroxynaphthalen-1-yl)benzamide	DMZHGP6	Discovery agent	N.A.	Investigative	[29]
4-butyl-N-(isoquinolin-5-yl)benzamide	DMHLQSE	Discovery agent	N.A.	Investigative	[29]
4-butyl-N-(pyridin-3-yl)benzamide	DMGW9XJ	Discovery agent	N.A.	Investigative	[29]
4-butyl-N-(quinolin-3-yl)benzamide	DMRMGWF	Discovery agent	N.A.	Investigative	[29]
4-butyl-N-phenylbenzamide	DMIMW1E	Discovery agent	N.A.	Investigative	[29]
4-decyl-N-(pyridin-3-yl)benzamide	DMGQTF9	Discovery agent	N.A.	Investigative	[29]
4-heptyl-N-(pyridin-3-yl)benzamide	DMA3MX5	Discovery agent	N.A.	Investigative	[29]
4-heptyl-N-(quinolin-3-yl)benzamide	DMAHLF6	Discovery agent	N.A.	Investigative	[29]
4-hexyl-N-(quinolin-3-yl)benzamide	DM5E03C	Discovery agent	N.A.	Investigative	[29]
4-nonyl-N-(quinolin-3-yl)benzamide	DMOW8TM	Discovery agent	N.A.	Investigative	[29]
4-octyl-N-(pyridin-3-yl)benzamide	DMNSU1H	Discovery agent	N.A.	Investigative	[29]
4-octyl-N-(quinolin-3-yl)benzamide	DMOGM3H	Discovery agent	N.A.	Investigative	[29]
4-pentyl-N-pyridin-3-yl benzamide	DMW198G	Discovery agent	N.A.	Investigative	[29]
4-propyl-N-(quinolin-3-yl)benzamide	DM4FLK6	Discovery agent	N.A.	Investigative	[29]
4-Pyridin-2-yl-piperazine-1-carboxylic acid amide	DMFC8Q4	Discovery agent	N.A.	Investigative	[32]
4-tert-butyl-N-(quinolin-3-yl)benzamide	DM1OBHQ	Discovery agent	N.A.	Investigative	[29]
5S-HETE	DM3Z6G4	Discovery agent	N.A.	Investigative	[19]
5S-HPETE	DME1304	Discovery agent	N.A.	Investigative	[28]
6'-Iodononivamide	DM0GSRL	Discovery agent	N.A.	Investigative	[33]
6-iodo-nordihydrocapsaicin	DM1S9DB	Discovery agent	N.A.	Investigative	[19]
A-795614	DM2W4IQ	Discovery agent	N.A.	Investigative	[34]
A-993610	DME4ULA	Pain	MG30-MG3Z	Investigative	[7]
A778317	DMG6ZHO	Discovery agent	N.A.	Investigative	[35]
ABT-116	DMJ6MUE	Pain	MG30-MG3Z	Investigative	[19]
agatoxin 489	DMAUJOM	Discovery agent	N.A.	Investigative	[36]
AMG 9810	DM589XV	Discovery agent	N.A.	Investigative	[37]
AMG-628	DMI39YX	Pain	MG30-MG3Z	Investigative	[38]
AMG-8563	DMU8M0I	Pain	MG30-MG3Z	Investigative	[7]
arvanil	DMO5LUF	Discovery agent	N.A.	Investigative	[39]
ASP-8370	DMFWTOP	Neuropathic pain	8E43.0	Investigative	[19]
ATC-120	DMIA2F1	Discovery agent	N.A.	Investigative	[40]
BCTC	DMT5AGJ	Pain	MG30-MG3Z	Investigative	[7]
CAPSAZEPINE	DM4ATCI	Discovery agent	N.A.	Investigative	[41]
diphenylboronic anhydride	DMRQZTS	Discovery agent	N.A.	Investigative	[19]
JNJ-17203212	DMDUWBF	Cough	MD12	Investigative	[41]
KJM429	DMPJKBV	N. A.	N. A.	Investigative	[42]
KMJ-372	DMP1GQB	Pain	MG30-MG3Z	Investigative	[19]
LASSBio-881	DMYNL40	Pain	MG30-MG3Z	Investigative	[19]
N-(4-iodophenyl)-4-(trifluoromethoxy)benzamide	DM6GFRP	Discovery agent	N.A.	Investigative	[43]
N-(4-iodophenyl)-4-(trifluoromethyl)benzamide	DMK9FQG	Discovery agent	N.A.	Investigative	[43]
N-(4-tert-butylphenyl)-4-(pyridin-2-yl)benzamide	DMN6DAZ	Discovery agent	N.A.	Investigative	[31]
N-methyl-4-pentyl-N-(pyridin-3-yl)benzamide	DMA0YGE	Discovery agent	N.A.	Investigative	[29]
N-[2-(5-hydroxy-1H-indol-3-yl)ethyl]lauramide	DM5FQH8	Discovery agent	N.A.	Investigative	[44]
N-[2-(5-hydroxy-1H-indol-3-yl)ethyl]linoleamide	DMG5PL7	Discovery agent	N.A.	Investigative	[44]
N-[2-(5-hydroxy-1H-indol-3-yl)ethyl]undecanamide	DMC1GYH	Discovery agent	N.A.	Investigative	[44]
NADA	DM3ORGM	Discovery agent	N.A.	Investigative	[19]
NE-28345	DMVSRYH	Discovery agent	N.A.	Investigative	[45]
phenylacetylrinvanil	DM29EFJ	Discovery agent	N.A.	Investigative	[46]
PPAHV	DMWVZFK	Discovery agent	N.A.	Investigative	[47]
Pyrrolidin-1-yl-thiourea	DMYNZXC	Discovery agent	N.A.	Investigative	[32]
SB-782443	DMYL56F	Discovery agent	N.A.	Investigative	[48]
SB452533	DMUFV4O	Discovery agent	N.A.	Investigative	[19]
SC-0030	DMD2WEQ	Discovery agent	N.A.	Investigative	[40]
[125I]resiniferatoxin	DMUD3A8	Discovery agent	N.A.	Investigative	[49]
[3H]A778317	DMVJKCH	Discovery agent	N.A.	Investigative	[35]
------------------------------------------------------------------------------------


⏷ Show the Full List of 75 Investigative Drug(s)

References

1	Capsaicin receptor: TRPV1 a promiscuous TRP channel. Handb Exp Pharmacol. 2007;(179):155-71.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	TRPV1 Antagonists as Analgesic Agents. The Open Pain Journal, 2013, 6, (Suppl 1: M11), 108-118 .
4	The discovery and development of analgesics: new mechanisms, new modalities. J Clin Invest. 2010 November 1; 120(11): 3753-3759.
5	Development of PAC-14028, a novel transient receptor potential vanilloid type 1 (TRPV1) channel antagonist as a new drug for refractory skin diseases. Arch Pharm Res. 2012 Mar;35(3):393-6.
6	Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
7	Analgesic potential of TRPV1 antagonists. Biochem Pharmacol. 2009 Aug 1;78(3):211-6.
8	An investigation of the safety and pharmacokinetics of the novel TRPV1 antagonist XEN-D0501 in healthy subjects. Br J Clin Pharmacol. 2011 Dec;72(6):921-31.
9	Clinical pipeline report, company report or official report of Biom Therapeutics
10	GRC-6211, a new oral specific TRPV1 antagonist, decreases bladder overactivity and noxious bladder input in cystitis animal models. J Urol. 2009 Jan;181(1):379-86.
11	Benzo[d]imidazole Transient Receptor Potential Vanilloid 1 Antagonists for the Treatment of Pain: Discovery of trans-2-(2-{2-[2-(4-Trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol (Mavatrep). J Med Chem. 2015 May 14;58(9):3859-74.
12	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030745)
13	Clinical pipeline report, company report or official report of pfizer.
14	Clinical pipeline report, company report or official report of Pharmeste.
15	Clinical pipeline report, company report or official report of Sanofi.
16	Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
17	Clinical pipeline report, company report or official report of AstraZeneca (2009).
18	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
19	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 507).
20	TRPV1: ON THE ROAD TO PAIN RELIEF. Curr Mol Pharmacol. 2008 November; 1(3): 255-269.
21	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
22	The taming of capsaicin. Reversal of the vanilloid activity of N-acylvanillamines by aromatic iodination. J Med Chem. 2005 Jul 14;48(14):4663-9.
23	Discovery of potent, orally available vanilloid receptor-1 antagonists. Structure-activity relationship of N-aryl cinnamides. J Med Chem. 2005 Jan 13;48(1):71-90.
24	Alpha-methylation at benzylic fragment of N-aryl-N'-benzyl ureas provides TRPV1 antagonists with better pharmacokinetic properties and higher effic... Bioorg Med Chem Lett. 2007 Jul 15;17(14):3894-9.
25	Rare dipeptide and urea derivatives from roots of Moringa oleifera as potential anti-inflammatory and antinociceptive agents. Eur J Med Chem. 2009 Jan;44(1):432-6.
26	Novel transient receptor potential vanilloid 1 receptor antagonists for the treatment of pain: structure-activity relationships for ureas with quin... J Med Chem. 2005 Feb 10;48(3):744-52.
27	In vitro structure-activity relationship and in vivo characterization of 1-(aryl)-3-(4-(amino)benzyl)urea transient receptor potential vanilloid 1 ... J Med Chem. 2007 Jul 26;50(15):3651-60.
28	Direct activation of capsaicin receptors by products of lipoxygenases: endogenous capsaicin-like substances. Proc Natl Acad Sci U S A. 2000 May 23;97(11):6155-60.
29	N-pyridin-3-yl- and N-quinolin-3-yl-benzamides: modulators of human vanilloid receptor 1 (TRPV1). Bioorg Med Chem Lett. 2008 Apr 15;18(8):2730-4.
30	2-aminoethoxydiphenyl borate is a common activator of TRPV1, TRPV2, and TRPV3. J Biol Chem. 2004 Aug 20;279(34):35741-8.
31	From arylureas to biarylamides to aminoquinazolines: discovery of a novel, potent TRPV1 antagonist. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5217-21.
32	N-4-methansulfonamidobenzyl-N'-2-substituted-4-tert-butyl-benzyl thioureas as potent vanilloid receptor antagonistic ligands. Bioorg Med Chem Lett. 2004 Apr 5;14(7):1693-6.
33	Halogenation of 4-hydroxy/amino-3-methoxyphenyl acetamide TRPV1 agonists showed enhanced antagonism to capsaicin. Bioorg Med Chem. 2010 Nov 15;18(22):8092-105.
34	Tetrahydropyridine-4-carboxamides as novel, potent transient receptor potential vanilloid 1 (TRPV1) antagonists. Bioorg Med Chem. 2008 Sep 15;16(18):8516-25.
35	[3H]A-778317 [1-((R)-5-tert-butyl-indan-1-yl)-3-isoquinolin-5-yl-urea]: a novel, stereoselective, high-affinity antagonist is a useful radioligand ... J Pharmacol Exp Ther. 2007 Oct;323(1):285-93.
36	An inhibitor of TRPV1 channels isolated from funnel Web spider venom. Biochemistry. 2005 Nov 29;44(47):15544-9.
37	AMG 9810 [(E)-3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo[b][1,4] dioxin-6-yl)acrylamide], a novel vanilloid receptor 1 (TRPV1) antagonist with antihyp... J Pharmacol Exp Ther. 2005 Apr;313(1):474-84.
38	Novel vanilloid receptor-1 antagonists: 3. The identification of a second-generation clinical candidate with improved physicochemical and pharmacok... J Med Chem. 2007 Jul 26;50(15):3528-39.
39	Cloning and pharmacological characterization of mouse TRPV1. Neurosci Lett. 2004 Nov 3;370(1):55-60.
40	Silicon switch approach in TRPV1 antagonist MK-056 and its analogues. Bioorg Med Chem. 2010 Jan 1;18(1):111-6.
41	The potential of transient receptor potential vanilloid type 1 channel modulators for the treatment of pain. J Med Chem. 2007 May 31;50(11):2589-96.
42	High affinity antagonists of the vanilloid receptor. Mol Pharmacol. 2002 Oct;62(4):947-56.
43	Synthesis of benzamide derivatives as TRPV1 antagonists. Bioorg Med Chem Lett. 2008 Feb 1;18(3):1072-8.
44	New N-arachidonoylserotonin analogues with potential "dual" mechanism of action against pain. J Med Chem. 2007 Dec 27;50(26):6554-69.
45	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
46	Development of the first ultra-potent "capsaicinoid" agonist at transient receptor potential vanilloid type 1 (TRPV1) channels and its therapeutic ... J Pharmacol Exp Ther. 2005 Feb;312(2):561-70.
47	Pharmacological differences between the human and rat vanilloid receptor 1 (VR1). Br J Pharmacol. 2001 Mar;132(5):1084-94.
48	Design and synthesis of 6-phenylnicotinamide derivatives as antagonists of TRPV1. Bioorg Med Chem Lett. 2008 Oct 15;18(20):5609-13.
49	Iodo-resiniferatoxin, a new potent vanilloid receptor antagonist. Mol Pharmacol. 2001 Jan;59(1):9-15.